Table 3.
Summary of patients’ previous therapies, including surgery, systemic chemotherapy, and, in the case of HCC, transarterial embolization – TACE.
| Previous therapy | Surgery | Systemic chemotherapy | Embolization | |||
|---|---|---|---|---|---|---|
| No | Type | No | type | No | Type | |
| HCC (N=4) | 2 | Hemihepatectomy | 3 | Sorafenib | 3 | TACE |
| mCRC (N=6) | 6 | Hemicolectomy left (N=4) and right (N=2) | 2 | FOLFOX-4 (1st line) FOLFIRI (2nd) | ||
| 2 | FOLFOX-4 (1st line), FOLFIRI (2nd) & Cetuximab (3rd) | |||||
| 4 | 2 | FOLFOX-4 (1st line), FOLFIRI (2nd) & Retuximab (3rd) | ||||
| NEC G3) (N=2) | 1 | Gastrectomy | 2 | PE (1st & 2nd line) | ||
| Ovarian ca (N=1), | 1 | Uterine, ovary and omentectomy | 1 | DDP + Taxol (1st line) & DDP + Gemcitabine (2nd) | ||
HCC – hepatocellular carcinoma; mCRC – metastatic Colorectal Cancer; NEC – neuroendocrine carcinoma (G3 – poorly differentiated); FOLFOX-4 - standard first- or second-line chemotherapy in patients with mCRC, this regimen consists of Folinic acid (leucovorin) + Fluorouracil (5FU) and Oxaliplatin; FOLFIRI – standard first or second line chemotherapy in patients with mCRC, this regiment consists of: Folinic acid (leucovorin) + Fluorouracil (5FU) and Irinotecan; PE – standard chemotherapy in advanced neuroendocrine carcinomas (poorly differentiated G3) – this regimen consists of Cisplatin and Etoposide; DDP+Taxol – standard chemotherapy in advanced ovarian cancer, this regiment consists of: Cisplatin and Taxol; DDP + Gemcitabine – second-line chemotherapy in patients with advanced ovarian cancer, this regiment consists of: Cisplatin and Gemcitabine.